• GW Pharma is touting claims that a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) produced positive survival benefits in a small study of 21 patients with recurrent glioblastoma multiforme, a common form of brain cancer. The drug arm had an 83 percent one year survival rate compared with 53 percent for patients in the placebo group. Drawing a direct link between the drug and survival in such a small group, though, is difficult to do. The company is now exploring a pivotal study.
• Belgian biotech Ablynx has filed for European approval of caplacizumab, which it describes as a first-in-class anti-von Willebrand factor Nanobody for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), an ultra-rare blood clotting disorder.
• J&J has handed over the rights to a heart drug to San Diego-based Renova Therapeutics. Renova says it is getting the investigational new drug file on stresscopin, which could play a role in treating acute decompensated heart failure, or ADHF. Renova says it now plans to advance the drug as RT-400 for a common disease with a 30% mortality rate. “Obtaining this stresscopin program IND helps propel forward the development of our peptide infusion product candidate, RT-400,” said Jack W. Reich, PhD, CEO and co-founder of Renova Therapeutics. “With this data, we hope to see promising results as we initiate pivotal trials.”
• Shanghai-based Abbisko Therapeutics raised a $28 million round, according to a report from BioCentury. CEO Yaochang Xu is a veteran of Novartis China and the biotech is working on preclinical immunomodulators for cancer. The money came from Lilly Asia Ventures, Sinopharm Capital, Jianxin Capital and TF Capital.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 29,000+ biopharma pros who read Endpoints News by email every day.Free Subscription